2. Disease Areas
  3. Musculoskeletal Disease
  4. Spinal Disease

Spinal Disease

Spinal disease refers to a group of conditions affecting the spine and its surrounding structures, leading to symptoms such as back or neck pain, numbness, tingling, muscle weakness, loss of bladder or bowel control, and abnormal spinal curvature like kyphosis. These disorders can result from various causes including congenital abnormalities, trauma, infections, inflammatory conditions, inherited genetic factors, degenerative changes, or complications such as syringomyelia—a chronic spinal cord disorder often developing prenatally or following injury, tumor, or disease. The condition may compress nerves or the spinal cord, resulting in neurological deficits and impaired mobility. Treatment varies based on severity and etiology, and may involve pain management, physical therapy, or surgical intervention. Key associated genes include SMN1, with connections to motor neuron function and immune signaling pathways. Affected tissues include bone and bone marrow, and clinical manifestations often relate to growth, body structure, and metabolic homeostasis.

References:

 

Spinal Disease (9):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N7700A
    Guluronic acid sodium 98.0%
    Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases.
    Guluronic acid sodium
  • HY-N7700
    Guluronic acid 15769-56-9 98.90%
    Guluronic acid (G2013) is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases.
    Guluronic acid
  • HY-19820A
    NSC45586 sodium 6300-44-3 98.0%
    NSC45586 sodium is an inhibitor of PHLPP. NSC45586 sodium targets the PP2C phosphatase domains of PHLPP1 and PHLPP2, blocks the phosphatase activity of PHLPP, increases the expression level of FOXO1 in the nucleus, and reduces the protein expression of PHLPP1. NSC45586 sodium activates the AKT survival signaling pathway, enhances IGF-1-induced AKT activation, and inhibits the phosphorylation of AKT/ERK under basal conditions. NSC45586 sodium reduces staurosporine-induced neuronal death, preserves notochord cell morphology and KRT19 expression, inhibits cell apoptosis (apoptosis), improves the viability and proliferation of nucleus pulposus cells, upregulates the expression of ACAN/SOX9, and downregulates the expression of MMP13. NSC45586 sodium binds tightly to bovine serum albumin (bovine serum albumin), and exerts a more significant effect on nucleus pulposus in male individuals. NSC45586 sodium can be used in studies related to global cerebral ischemia and intervertebral disc degeneration.
    NSC45586 sodium
  • HY-N6701
    Dihydrocytochalasin B 39156-67-7 99.0%
    Dihydrocytochalasin B is an Actin disruptor. Dihydrocytochalasin B disrupts actin microfilament bundles, inhibits actin polymerization, and alters intracellular actin cytoskeletal structures. Dihydrocytochalasin B blocks the initiation of DNA synthesis. Dihydrocytochalasin B inhibits Calcium transport. Dihydrocytochalasin B inhibits cytokinesis and alters cell morphology. Dihydrocytochalasin B can be used in studies related to rickets.
    Dihydrocytochalasin B
  • HY-P5542
    Vicatertide 1251838-01-3 99.24%
    Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a Ka of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases.
    Vicatertide
  • HY-P99335
    Vunakizumab 1792181-33-9
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis.
    Vunakizumab
  • HY-114164G
    Murine Thrombin 9002-04-4
    Murine Thrombin is a murine serine protease that plays a central role in blood coagulation. Murine Thrombin stimulates macrophages to polarize into a unique phenotype characterized by anti-inflammatory and pro-repair properties. Murine Thrombin activates PAR1, induces the production of MCP-1, MMP3 and VEGF in mouse intervertebral discs, and causes degradation of the cartilage matrix and destruction of intervertebral disc structure. Murine Thrombin activity increases significantly in paraoxon-induced status epilepticus.
    Murine Thrombin
  • HY-P99754
    Netakimab 1796570-08-5
    Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Netakimab
  • HY-110067
    VO-OHPic 675848-25-6
    VO-OHPic is a reversible, noncompetitive PTEN inhibitor with an human IC50 value of 46 nM. VO-OHPic inhibits PTEN signaling, activates Akt-GSK3β and Nrf-2/HO-1 pathways, induces apoptosis resistance and elevates IL-10 levels. VO-OHPic inhibits autophagy, ferroptosis and oxidative stress. VO-OHPic can be used for the research of acute myocardial infarction, intervertebral disc degeneration, cardiomyopathy and cancer.
    VO-OHPic